Where pharmaceutical workforce complexity meets HCM that handles it.

UKG Pro is where most of our domestic pharma implementation depth sits. For multi-country payroll, we work across the platform landscape pharma actually runs on: the ADP global suite (Workforce Now, Celergo, GlobalView, Streamline) and UKG One View as primary platforms, plus EOR and global payroll providers (Deel, Alight, TMF Group, Northgate Arinso) when client architecture calls for them. Pharma buyers tend to evaluate platforms against operational complexity, not feature lists, and our portfolio reflects that. The 100+ HCM implementations behind the practice include multi-country pharma engagements across 70+ countries, each with its own labor law layer, statutory benefits framework, and payroll cycle. Our advisory work stays platform-agnostic. Our implementation work goes platform-deep at the configuration layer where multi-country architecture, milestone compensation, and regulatory reporting actually live.

We design multi-country payroll architectures at the country layer, not as a global template with country exceptions bolted on. Each country runs its own local reality cleanly (labor law, statutory benefits, currency, payroll cycles, reporting cadences, year-end requirements), and global consolidation pulls audit-clean data without after-the-fact reconciliation. Global mobility integrates at the same layer: expatriate compensation, tax equalization, hypothetical tax calculations, and secondment structures all flow through configurations that survive the moment when assignments extend or change shape mid-cycle. Close cadence holds: each country closes on its statutory schedule, global consolidation pulls when local closes complete, and finance receives data already reconciled rather than reconciled after the fact. The architecture handles operational reality, not idealized global standards that don't survive contact with local labor law.

We work big pharma and specialty pharma, with the deepest portfolio in big pharma. Big pharma is where multi-country complexity, R&D workforce scale, commercial sales force structures, and the full regulatory landscape converge in one organization. Specialty pharma carries different complexity profiles: typically narrower geographic footprint, milestone-heavy compensation around single-product or pipeline-focused R&D, and tighter commercial models. Biotech carries similar dynamics to specialty pharma at smaller scale: milestone-heavy R&D compensation, pipeline-focused workforces, and the operational realities of pre-commercial or early-commercial organizations. Engagement shape adjusts to what the workforce actually needs, not to a template assumption about pharma scale.

Vendor professional services teams are good at getting the platform stood up. They're not always set up to handle pharma's specific complexity: multi-country payroll architectures, milestone-driven compensation structures, clinical trial labor allocation, and the regulatory reporting that has to flow from payroll rather than parallel to it. We work alongside the vendor's professional services team when the engagement structure calls for it, and we work in their place when the client wants pharma-specific depth on the implementation team. Our team carries UKG platform certification depth comparable to vendor professional services teams (25 UKG-certified consultants firm-wide), with pharma-specific operational depth from the consultants we staff to pharma engagements. Either way, we own the configurations that have to keep working through the next product launch, the next country expansion, and the next regulatory framework update.

Transparency reporting works correctly when it flows from the system that ran the underlying transactions, not from a parallel compliance system reconciling back to it. We design HCM and payroll configurations where transfers of value between the manufacturer and healthcare professionals (employment-related payments, consulting arrangements, research support, advisory board honoraria) are tagged at the source, with the data that supports federal Open Payments submissions and state-level reporting requirements (Vermont, Massachusetts, Minnesota, and others) generated from the configuration that ran the work. State and federal frameworks compound rather than substitute. Vermont, Massachusetts, Minnesota, and others each carry their own thresholds, payment categories, and submission formats, layered onto the federal Open Payments baseline. Payment categories that look adjacent at a glance (research support paid through a covered recipient versus direct, advisory board honoraria timing-of-service versus payment, in-kind transfers documented at fair market value) require different tagging logic at the source. We configure for the layered framework from the start, with audit trails that reconstruct each transfer of value back to the underlying employment, consulting, or research arrangement that produced it.

Audit-readiness in clinical trial labor isn't a separate deliverable. It's what you get when labor allocation, time tracking, and sponsor reporting are configured correctly to begin with. We design HCM configurations that allocate labor at the trial layer, track time against trial-specific cost objectives, and produce sponsor-ready reporting that ties back to the workforce structure that ran the trial. Trial-specific cost objects encode at the configuration layer: protocol IDs, study sites, phase gates, and milestone events all carry their own tagging logic so that effort certification and labor allocation reporting reconcile cleanly against trial accounting. When sponsor audits, internal Quality Assurance reviews, or regulatory inspections request labor allocation documentation, the system produces it from the configuration that ran the work, not from a parallel time tracking system that has to be reconciled afterward. GxP-environment configurations carry the validation documentation, change control records, and access trails that regulatory inspections expect to see.

Commercial incentive compensation (IC) plans in pharma rarely sit still. Product launches add quota carve-outs. Indication expansions reshape territory assignments. Competitive dynamics drive contest cycles, SPIFFs, and clawback provisions. Plan transitions often run multiple plan versions live simultaneously across a transition period, with reps' actual payouts touching multiple plans for the same selling period. We design IC engines that handle multi-plan complexity, portfolio-spanning quota structures, and payout reconciliation across plan versions, without forcing the commercial reality into a generic sales comp template that breaks at the next product launch or therapy area expansion. Retroactive plan adjustments resolve at the engine layer too: when a plan version updates mid-quarter or quotas re-baseline after an indication launch, the system recalculates affected payouts back through the transition period and surfaces the deltas without manual workbook reconciliation.

Success means the configuration produces correct outputs from the system that ran the work, without parallel reconciliation systems sitting in front of regulators or sponsors. Federal Open Payments and state-level transparency submissions draw from the same configuration that ran the underlying transfers of value, with audit trails that reconstruct each entry. Clinical trial sponsor audits and GxP regulatory inspections receive labor allocation documentation produced from the trial-specific cost objects that ran the time and effort. Multi-country payroll closes on each country's statutory schedule, and global consolidation pulls audit-clean data when the local closes complete. Commercial IC payouts resolve cleanly across plan versions even when product launches or indication expansions re-baseline quotas mid-cycle. The harder-to-quantify signal is operational: quarterly close cycles return to operational analysis rather than reconciliation between systems.